The presence of glutamic acid at positions 71 or 74 in pocket 4 of the HLA-DRβ1 chain is associated with the clinical course of multiple sclerosis
暂无分享,去创建一个
M. Pender | J. Greer | J M Greer | M P Pender
[1] J. Hillert,et al. An immunogenetic heterogeneity in multiple sclerosis , 1991, Journal of Neuroimmunology.
[2] M. Pender,et al. Increased circulating T cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis , 2003, Journal of Clinical Neuroscience.
[3] N. Hellings,et al. Insights into the immunopathogenesis of multiple sclerosis , 2002, Immunologic research.
[4] Z. Meiner,et al. HLA class II susceptibility to multiple sclerosis among Ashkenazi and non-Ashkenazi Jews. , 1999, Archives of neurology.
[5] J. Hillert,et al. HLA‐DR15 is associated with lower age at onset in multiple sclerosis , 2000, Annals of neurology.
[6] T. Olsson,et al. Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[7] J. Baskerville,et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. , 1999, Brain : a journal of neurology.
[8] F. Christiansen,et al. The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases , 1999, Immunological reviews.
[9] P. Fernlund,et al. HLA-DQ genotypes in classic type 1 diabetes and in latent autoimmune diabetes of the adult. , 2002, American journal of epidemiology.
[10] D. Li,et al. Clinical presentation of primary progressive multiple sclerosis 10 years after the incidental finding of typical magnetic resonance imaging brain lesions , 2003, Multiple sclerosis.
[11] R. Vaughan,et al. HLA-DR and -DQ associations with multiple sclerosis in Turkey. , 1997, Human immunology.
[12] A. Thompson,et al. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. , 1990, BMJ.
[13] N. Guex,et al. SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.
[14] J. Hillert,et al. Multiple sclerosis is associated with genes within or close to the HLA‐DR‐DQ subregion on a normal DR15, DQ6, Dw2 haplotype , 1993, Neurology.
[15] Don C. Wiley,et al. Crystal Structure of HLA-DR2 (DRA*0101, DRB1*1501) Complexed with a Peptide from Human Myelin Basic Protein , 1998, The Journal of experimental medicine.
[16] H. Weiner,et al. Extended major histocompatibility complex haplotypes in patients with multiple sclerosis , 1989, Neurology.
[17] L. Barcellos,et al. Evidence for the genetic role of human leukocyte antigens in low frequency DRBI*1501 multiple sclerosis patients in Israel , 1999, Multiple sclerosis.
[18] D. Schaid,et al. Major histocompatibility complex class II alleles and the course and outcome of MS , 1998, Neurology.
[19] G. McDonnell,et al. Major histocompatibility complex class II alleles and the course and outcome of MS. , 1999, Neurology.
[20] R. Karr,et al. Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association , 1995, The Journal of experimental medicine.
[21] D. Silberberg,et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.
[22] A. Compston,et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.
[23] T. Sasazuki,et al. A new predictive model for insulin-dependent diabetes mellitus susceptibility based on combinations of molecular HLA-DRB1 and HLA-DQB1 pockets. , 1999, Tissue antigens.
[24] Don C. Wiley,et al. Structure of a Complex of the Human α/β T Cell Receptor (TCR) HA1.7, Influenza Hemagglutinin Peptide, and Major Histocompatibility Complex Class II Molecule, HLA-DR4 (DRA0101 and DRB10401) , 2002, The Journal of experimental medicine.
[25] A. Sette,et al. Pocket 4 of the HLA-DR(alpha,beta 1*0401) molecule is a major determinant of T cells recognition of peptide , 1995, The Journal of experimental medicine.
[26] M. Pender,et al. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis , 1998, Annals of neurology.
[27] Robert D. Henderson,et al. The occurrence of autoimmune diseases in patients with multiple sclerosis and their families , 2000, Journal of Clinical Neuroscience.
[28] T. Wienker,et al. Multiple sclerosis associated amino acids of polymorphic regions relevant for the HLA antigen binding are confined to HLA-DR2. , 2000, Human immunology.
[29] Shirley A. Miller,et al. A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.
[30] R. Karr,et al. Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[31] H. Harbo,et al. Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis , 2000, Journal of the Neurological Sciences.
[32] D. McFarlin,et al. Immunological aspects of demyelinating diseases. , 1992, Annual review of immunology.
[33] L. Richeldi,et al. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. , 1993, Science.
[34] F. Muntoni,et al. DRB1-DQA1-DQB1 loci and multiple sclerosis predisposition in the Sardinian population. , 1998, Human molecular genetics.
[35] R. Papais-Alvarenga,et al. DQB1*0602 confers genetic susceptibility to multiple sclerosis in Afro-Brazilians. , 1999, Tissue antigens.
[36] D. Middleton,et al. A study of the HLA-DR region in clinical subgroups of multiple sclerosis and its influence on prognosis , 1999, Journal of the Neurological Sciences.
[37] C. Nevinny-Stickel,et al. Susceptible and protective major histocompatibility complex class II alleles in early-onset pauciarticular juvenile chronic arthritis. , 1994, Human immunology.
[38] P. Vermersch,et al. Distortion of the Self-Reactive IgG Antibody Repertoire in Multiple Sclerosis as a New Diagnostic Tool1 , 2004, The Journal of Immunology.
[39] Junya Chen,et al. HLA and hypertrophic Hashimoto's thyroiditis in Shanghai Chinese. , 1988, Tissue antigens.
[40] E. Husebye,et al. Autoimmune adrenocortical failure in Norway autoantibodies and human leukocyte antigen class II associations related to clinical features. , 2002, The Journal of clinical endocrinology and metabolism.
[41] U. Wagner,et al. Prognostic use of human leukocyte antigen genotyping for rheumatoid arthritis susceptibility, disease course, and clinical stratification. , 2002, Rheumatic diseases clinics of North America.
[42] M. Pender,et al. Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. , 1997, Brain : a journal of neurology.
[43] B Bass,et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.
[44] G. McDonnell,et al. Primary progressive multiple sclerosis: increasing clarity but many unanswered questions , 2002, Journal of the Neurological Sciences.
[45] M. Maiers,et al. The HLA Dictionary 2001: a summary of HLA-A, -B, -C, -DRB1/3/4/5, -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR and -DQ antigens. , 2001, Tissue antigens.
[46] J. Frank,et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand , 2000, Nature Medicine.
[47] J. Granados,et al. HLA class II genotypes in Mexican Mestizos with familial and nonfamilial multiple sclerosis , 2000, Neurology.
[48] Don C. Wiley,et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide , 1994, Nature.
[49] J. Ilonen,et al. Humoral beta-cell autoimmunity in relation to HLA-defined disease susceptibility in preclinical and clinical type 1 diabetes. , 2002, American journal of medical genetics.
[50] J. Whitaker,et al. Clinical and laboratory features of primary progressive and secondary progressive MS , 1999, Neurology.
[51] G. Stewart,et al. HLA-DW2, viral immunity and family studies in multiple sclerosis , 1977, Journal of the Neurological Sciences.
[52] J. Hillert,et al. HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. , 1991, Tissue antigens.
[53] S. Leeder,et al. A population based study , 1993, The Medical journal of Australia.